Successful Treatment of Posttransplant Recurrent Complement C3 Glomerulopathy with Eculizumab

Sahin H., Oguz E. G. , Akoglu H. , Atilgan G., Okyay G. U. , Gursoy G. K. , ...Daha Fazla

IRANIAN JOURNAL OF KIDNEY DISEASES, cilt.12, ss.315-318, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 12 Konu: 5
  • Basım Tarihi: 2018
  • Sayfa Sayıları: ss.315-318


Two-thirds of complement C3 glomerulopathy (C3G) recur after transplantation and commonly cause graft loss. There is not a standard treatment protocol for these cases. We present a kidney transplant patient with recurrent C3G who was successfully treated with eculizumab. Nephrotic proteinuria and hernaturia occurred and creatinine levels increased after transplantation. A graft biopsy revealed recurrent C3G. The patient was administered 250 mg pulse methylprednisolone for 3 days and had 9 sessions of plasmapheresis. Since elevated creatinine levels and proteinuria persisted, eculizumab was instituted. A complete remission was observed after 9-month maintenance eculizumab treatment. Eculizumab may be a potentially effective option in kidney transplant patients with recurrent C3G unresponsive to other treatment modalities.